<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221061</url>
  </required_header>
  <id_info>
    <org_study_id>833963</org_study_id>
    <nct_id>NCT04221061</nct_id>
  </id_info>
  <brief_title>A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma</brief_title>
  <official_title>A Pilot Study Evaluating in Vivo PARP-1 Expression with18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The subject will be a candidate for this imaging study because they have agreed to&#xD;
      participate in a treatment study involving TTFields (Optune device), a device that uses low&#xD;
      intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research&#xD;
      study is being conducted to test how a new radioactive imaging drug called&#xD;
      18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or&#xD;
      after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron&#xD;
      Emission Tomography/Computed Tomography (PET/CT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">December 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluate uptake of [18F]FTT in recurrent glioblastoma after initiation of TTFields therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of &quot;BRCAness&quot;.</measure>
    <time_frame>3 years</time_frame>
    <description>Correlate [18F]FTT uptake measures with Homologous recombination deficiency (HRD) status or other markers of &quot;BRCAness&quot;.&#xD;
To determine pre-/post-treatment changes in [18F]FTT uptake after initiation of TTFields therapy.&#xD;
To determine pre-/post-treatment changes in [18F]FTT uptake after initiation of PARP inhibitor.&#xD;
To correlate PARP expression by pathology testing with uptake of [18F]FTT in surgical subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Non-surgical candidates</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical candidates</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-FluorThanatrace</intervention_name>
    <description>18F-FluorThanatrace is a novel radiopharmaceutical which measure PARP-1 expression using a Positron Emission Tomography (PET/CT) scan.</description>
    <arm_group_label>Non-surgical candidates</arm_group_label>
    <arm_group_label>Surgical candidates</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants will be â‰¥ 22 years of age&#xD;
&#xD;
          2. Participants will have a diagnosis of glioblastoma and be enrolled in the companion&#xD;
             treatment trial, IRB 832694.&#xD;
&#xD;
          3. Participants must be informed of the investigational nature of this study and be&#xD;
             willing to provide written informed consent and participate in this study in&#xD;
             accordance with institutional and federal guidelines prior to study-specific&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or breast-feeding at the time of screening will not be&#xD;
             eligible for this study; a urine pregnancy test will be performed in women of&#xD;
             childbearing potential at screening.&#xD;
&#xD;
          2. Inability to tolerate imaging procedures in the opinion of an investigator or treating&#xD;
             physician.&#xD;
&#xD;
        Any current medical condition, illness, or disorder as assessed by medical record review&#xD;
        and/or self-reported that is considered by a physician investigator to be a condition that&#xD;
        could compromise participant safety or successful participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maha Ayub</last_name>
    <phone>2158984346</phone>
    <phone_ext>2157463230</phone_ext>
    <email>maha.ayub@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zeinab Helili</last_name>
    <phone>2157463230</phone>
    <phone_ext>2157463230</phone_ext>
    <email>zeinab.helili@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Ayub</last_name>
      <phone>215-898-4346</phone>
      <phone_ext>2158984346</phone_ext>
      <email>maha.ayub@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maha Ayub</last_name>
      <phone>2158984346</phone>
      <phone_ext>2158984346</phone_ext>
      <email>maha.ayub@pennmedicine.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

